A unique new study led by Professor Gilles-Eric Seralini has shown that the first genetically-modified GM crop commercialized for animal feed, Bt176 from Novartis (now Syngenta), was toxic to cows over the long-term.
The first GM maize to be commercialized for animal feed, Bt176 from Novartis (subsequently Syngenta), caused various controversies, beginning in 1996. Grown on a few thousand hectares, it was quickly withdrawn from the market.
An antibiotic resistance marker gene was used in the genetic transformation, and the plant produced a new modified insecticide like all Bt plants. Yet only one nutritional test was conducted by Novartis on four cows for two weeks; one cow died after a week without scientific explanation.
– Blows Against Big Pharma and Its Vaccine Culture Fortress (Activist Post, Jan 18, 2013):
Do you hear it happening? Do you hear the emerging discontent within the infrastructure that, up-until-now, Big Pharma was capable of preventing from happening around their ‘sacred cows’—vaccines and pharmaceuticals, aka legal drugs? How many prescription drugs are senior citizens prescribed and how many vaccines do infants receive in their first year of life? All are destined to become legal ‘druggies’ from the beginning to the end of their lives.
If you are not aware, some within medicine and the pharmaceutical industry are coming out of the closet about vaccines. They are becoming conscious struck, and thankfully so. It seems the children’s story with the Emperor’s New Clothes story line is just too much for many, who know factual science and medicine, to keep swallowing like the Kool Aid Jim Jones mandated his followers take—even to their deaths.
Small clumps of virus particles found in some batches, affecting efficacy but not safety
– Health Canada pulls distribution of Novartis flu vaccines (CBC News, Oct, 27, 2012):
Canada is following the lead of several European countries and suspending distribution of flu vaccine made by the pharmaceutical firm Novartis.
The decision relates to the discovery by the company of tiny clumps of virus particles in some batches of flu vaccines made at the Novartis production facility in Italy.
Saskatchewan clinics closed
Saskatchewan has temporarily shut its public influenza immunization clinics in response to news about the Novartis products.
“Thanks to the fantastic work of Bilderberg activists, journalists and the Swiss media, we have now been able to obtain the full official list of 2011 Bilderberg attendees. Routinely, some members request that their names be kept off the roster so there will be additional Bilderbergers in attendance.
- Coene, Luc, Governor, National Bank of Belgium
- Davignon, Etienne, Minister of State
- Leysen, Thomas, Chairman, Umicore
- Fu, Ying, Vice Minister of Foreign Affairs
- Huang, Yiping, Professor of Economics, China Center for Economic Research, Peking University
- Eldrup, Anders, CEO, DONG Energy
- Federspiel, Ulrik, Vice President, Global Affairs, Haldor Topsøe A/S
- Schütze, Peter, Member of the Executive Management, Nordea Bank AB
- Ackermann, Josef, Chairman of the Management Board and the Group Executive Committee, Deutsche Bank
- Enders, Thomas, CEO, Airbus SAS
- Löscher, Peter, President and CEO, Siemens AG
- Nass, Matthias, Chief International Correspondent, Die Zeit
- Steinbrück, Peer, Member of the Bundestag; Former Minister of Finance
NEW YORK (Reuters) – Novartis AG plans to seek regulatory approval within 18 months for a pioneering tablet containing an embedded microchip, bringing the concept of “smart-pill” technology a step closer.
The initial program will use one of the Swiss firm’s established drugs taken by transplant patients to avoid organ rejection. But Trevor Mundel, global head of development, believes the concept can be applied to many other pills.
“We are taking forward this transplant drug with a chip and we hope within the next 18 months to have something that we will be able to submit to the regulators, at least in Europe,” Mundel told the Reuters Health Summit in New York.
“I see the promise as going much beyond that,” he added.
Novartis agreed in January to spend $24 million to secure access to chip-in-a-pill technology developed by privately owned Proteus Biomedical of Redwood City, California, putting it ahead of rivals.
possibly intentionally go wrong?
Oct. 7 (Bloomberg) — Novartis AG agreed to use technology from Synthetic Genomics Vaccines Inc., a company run by genome pioneer Craig Venter, in an effort to cut the time needed to develop influenza shots.
Novartis and San Diego-based Synthetic Genomic Vaccines will work together to create so-called seed viruses, templates from which large amounts of vaccine are created, Novartis said in a statement today. Novartis hopes to reduce the time needed to start vaccine output by two months, which is critical in the case of a flu pandemic, the company said.
“There is always the risk a of pandemic,” Rino Rappuoli, who heads vaccine research at Basel, Switzerland-based Novartis, said in a telephone interview today. The company produced enough vaccine only after the peak of the flu pandemic was over last year, Rappuoli said.
The future: No chance to discontinue the medicine!
(Financial Times) Patients who fail to pop pills on time could soon benefit from having a chip on their shoulder, under a ground-breaking electronic system being developed by Novartis, the Swiss pharmaceuticals group.
The company is testing technology that inserts a tiny microchip into each pill swallowed and sends a reminder to patients by text message if they fail to follow their doctors’ prescriptions.
The partnership with Proteus Biomedical, which originally developed the technology, is one of several alliances under development by Novartis as it and rival pharmaceuticals companies attempt to maintain high prices for innovative medicines by ensuring that they are taken as the doctor ordered. Pfizer’s Health Solutions division has developed a system to telephone patients to encourage them to take medicine.
Joe Jimenez, head of pharmaceuticals at Novartis, said tests using the system – which broadcasts from the “chip in the pill” to a receiver on the shoulder – on 20 patients using Diovan, a drug to lower blood pressure, had boosted “compliance” with prescriptions from 30 per cent to 80 per cent after six months.
The swine flu vaccine has been hit by new cancer fears after a German health expert gave a shock warning about its safety.
Dr. Wolfgang Wodarg
Dr. Wolfgang Wodarg is a politician and a specialist in lungs, hygiene and environmental medicine. He is the chairman of the health committee in the German parliament and European Council.
Wolfgang Wodarg has said that there are many risks associated with the vaccine for the H1N1 virus.
He has grave reservations about the firm Novartis who are developing the vaccine and testing it in Germany. The vaccination is injected “with a very hot needle”, Wodarg said.
The nutrient solution for the vaccine consists of cancerous cells from animals and “we do not know if there could be an allergic reaction”.
But more importantly, some people fear that the risk of cancer could be increased by injecting the cells.
The vaccine – as Johannes Löwer, president of the Paul Ehrlich Institute, has pointed out – can also cause worse side effects than the actual swine flu virus.
Wodrag also described people’s fear of the pandemic as an “orchestration”: “It is great business for the pharmaceutical industry,” he told the ‘Neuen Presse’.
Swine flu is not very different from normal flu. “On the contrary if you look at the number of cases it is nothing compared to a normal flu outbreak,” he added.
The chairman of the health committee in the European Council has urged for a careful and calm reaction to the virus.